Prevalence and Severity of Diabetic Retinopathy in Patients with Macular Telangiectasia Type 2.


Journal

Ophthalmology. Retina
ISSN: 2468-6530
Titre abrégé: Ophthalmol Retina
Pays: United States
ID NLM: 101695048

Informations de publication

Date de publication:
10 2021
Historique:
received: 12 09 2020
revised: 16 12 2020
accepted: 04 01 2021
pubmed: 15 1 2021
medline: 8 1 2022
entrez: 14 1 2021
Statut: ppublish

Résumé

To study the prevalence and severity of diabetic retinopathy (DR) in patients with macular telangiectasia type 2 (MacTel 2). Retrospective case series. Patients with a diagnosis of MacTel 2 treated at the Rotterdam Eye Hospital or Erasmus Medical Center between 2014 and 2018 were included. The following information was retrieved from patient files: demographics, history of diabetes mellitus and hypertension, presence of DR, and severity of DR, that is, mild, moderate, severe, or proliferative. Presence of diabetic macular edema (DME) was assessed using OCT. Presence and severity of DR. Two hundred six eyes of 103 patients were included. At the onset of MacTel 2, the mean age was 61 years (standard deviation [SD], 9.8 years) and 64 (62%) were women. Mean follow-up was 71 months (SD, 60 months). Diabetes mellitus type 2 was present in 50 patients (49%) and hypertension was present in 47 patients (46%). Mild DR was present in 22 eyes (11%), of which 14 eyes (7%) showed signs at baseline and 8 eyes (4%) showed signs at a later time during follow-up. Ten eyes (5%) demonstrated remission of mild DR during follow-up. Both eyes (1%) in 1 patient progressed to moderate DR. Severe DR, proliferative DR, and DME did not occur. Although diabetes mellitus was highly prevalent among MacTel 2 patients, no patients showed severe or proliferative DR or DME. These findings suggest that MacTel 2 could have a protective effect on the progression of DR. We hypothesize that our results may be explained by the role of Müller cells in the development of MacTel 2 and DR, and therefore a link between both diseases warrants additional studies.

Identifiants

pubmed: 33444807
pii: S2468-6530(21)00012-9
doi: 10.1016/j.oret.2021.01.002
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

999-1004

Informations de copyright

Copyright © 2021 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Auteurs

Saskia H M van Romunde (SHM)

Rotterdam Eye Hospital, Rotterdam, The Netherlands. Electronic address: saskia.vanromunde@gmail.com.

Charlotte M van der Sommen (CM)

Rotterdam Eye Hospital, Rotterdam, The Netherlands.

José P Martinez Ciriano (JP)

Rotterdam Eye Hospital, Rotterdam, The Netherlands.

Johannes R Vingerling (JR)

Department of Ophthalmology, Erasmus Medisch Centrum, Rotterdam, The Netherlands.

Suzanne Yzer (S)

Rotterdam Eye Hospital, Rotterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH